20 November 2019 - - US-based diagnostics developer Prevencio, Inc is highlighting data it said confirms the high accuracy of its AI-driven, multiple-protein HART CADhs test, a biomarker clinical/proteomic panel inclusive of high sensitivity cardiac troponin for the diagnosis of obstructive Coronary Artery Disease, also known as heart disease, the company said.
Researchers highlighted that these important findings, presented November 18 at the 2019 American Heart Association Scientific Sessions in Philadelphia, performed with high accuracy on two different patient groups from Massachusetts General Hospital and The University Heart Center, Hamburg, Germany.
HART CADhs data from 1,152 patients were presented as "Derivation and External Validation of a High Sensitivity Troponin Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease: Value in the Troponin Indeterminant Zone."
In this study, HART CADhs test was developed from 636 patient blood samples from MGH.
The HART CADhs test was then internally validated on 275 different patients from MGH and finally was positively validated on 241 patients who presented to the ED with heart attack suspicion at The University Heart Center, Hamburg, Germany.
Notably, performance of HART CADhs test was strong among UHC ED patients in the troponin indeterminant zone (patients who were neither rule-in nor rule-out for heart attack, but there were concerns for heart artery obstruction which could cause a heart attack in the near-term).
Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease. Employing this novel approach, the company has developed six blood tests to-date that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
HART test results have been presented at leading cardiovascular meetings--(European Society of Cardiology Congress Scientific Sessions 2016 and 2018, American College of Cardiology Scientific Sessions 2017, 2018 and 2019, American Heart Association Scientific Sessions 2017, 2018 and 2019, and American Diabetes Association Scientific Sessions 2018) and published in top-tier cardiology journals--(Journal of American College of Cardiology March 2017, American Journal of Cardiology July 2017, Open Heart November 2018 and Clinical Cardiology June 2018 and January 2019).
Prevencio utilises Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic and prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores.
The company is headquartered in Kirkland, Washington.